Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Aurobindo Pharma Limited

Aurobindo Pharma is a fully integrated pharmaceutical company that manufactures and sells a wide range of products globally, with specific focus on active pharmaceutical ingredients and formulations. The company exports to over 150 countries, with a major share of its revenue from international operations.

msh id	COM:AUROBINDO
symbol	AUROPHARMA
name	Aurobindo Pharma Limited
homepage url	https://www.aurobindo.com
country	IN
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	23.45K
crunchbase url	-
linkedin url	-
founders	-

market cap	9.18B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.1
growth cost of revenue	0.11
growth depreciation and amortization	0.1
growth ebitda	-0.13
growth ebitda ratio	-0.18
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.03
growth gross profit	0.01
growth gross profit ratio	-0.04

COM:AUROBINDO

Aurobindo Pharma

Last Close

1,250.10

21/11 09:59

Market Cap

772.21B

Beta: -

Volume Today

397.95K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	2.4B
cost of revenue	2.4B
depreciation and amortization	134.91M
ebitda	553.42M
ebitda ratio	0.2
eps	0.54
eps diluted	0.54
operating expenses	1.19B
operating income	418.5M
operating income ratio	0.15

accounts receivables	-51.75M
capital expenditure	-325.8M
cash at beginning of period	498.51M
cash at end of period	526.02M
inventory	904.66M
working capital ttm	105.43B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-